Erlotinib-induced Rosacea-like Dermatitis.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Cutaneous toxicities are common side effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
• These EGFR-TKI-induced skin reactions are typically transient, reversible, and dose-dependent, affecting patient quality of life and treatment adherence.
• Common presentations include papulopustules on an erythematous base, often termed 'acneiform' eruptions.

Observation:

• A 77-year-old male with non-small cell lung cancer treated with erlotinib developed a centrofacial rosacea-like rash.
• The patient had no prior history of rosacea, suggesting the rash was an adverse reaction to EGFR-TKI therapy.
• This presentation differs from the commonly described acneiform or papulopustular lesions.

Findings:

• The case highlights rosacea-like dermatitis as a potential, less recognized cutaneous side effect of EGFR-TKIs.
• Current terminology for EGFR-TKI skin toxicities may overlook or misdiagnose less common presentations like rosacea-like dermatitis.
• The patient's symptoms were likely an adverse reaction to erlotinib, an EGFR-TKI.

Implications:

• Accurate classification of EGFR-TKI-induced cutaneous adverse reactions is crucial for early detection and appropriate management.
• Recognizing less common side effects like rosacea-like dermatitis can prevent misdiagnosis and ensure timely, specific treatment.
• Improved classification supports continued oncological therapy by effectively managing side effects, thereby improving patient compliance and outcomes.